Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score

by Stuart C. Gordon, Nandita Kachru, Emily Parker, Stephanie Korrer, A. Burak Ozbay, Robert J. Wong
Published 2020-07-01

Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials.

by Tram T Tran, Stuart C Gordon, Scott Fung, Phillip Dinh, Leland Yee, Eduardo Bruno Martins, Maria Buti, Patrick Marcellin
Published 2015-01-01

Baricitinib and primary biliary cholangitis

by Stuart C. Gordon, Sheri Trudeau, Arie Regev, Jonathan M. Uhas, Sujatro Chakladar, Ana Pinto-Correia, Klaus Gottlieb, Doug Schlichting
Published 2021-01-01

Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure

by Philip R. Spradling, Yuna Zhong, Anne C. Moorman, Loralee B. Rupp, Mei Lu, Stuart C. Gordon, Eyasu H. Teshale, Mark A. Schmidt, Yihe G. Daida, Joseph A. Boscarino, for the Chronic Hepatitis Cohort Study (CHeCS) Investigators
Published 2021-03-01

P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis

by Massimo Puoti, Graham Foster, Stanley Wang, David Mutimer, Edward Gane, Christophe Moreno, Ting Tsung Chang, SamS Lee, Rui Marinho, Jean-Francois DuFour, Stanislas Pol, Christophe Hezode, Stuart C. Gordon, Simone I. Strasser, Paul J. Thuluvath, Ran Liu, Tami Pilot-Matias, Federico Mensa
Published 2017-08-01

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure

by Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih-Wei Lin, Yang Lei, Teresa I. Ng, Tami Pilot-Matias, Jens Kort, Federico Mensa
Published 2017-08-01

P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies

by Stuart K. Roberts, Curtis L. Cooper, Eric Lawitz, K. Rajender Reddy, Alex J. Thompson, Stefan Zeuzem, Ira M. Jacobson, Peter Ruane, Robert H. Hyland, Luisa M. Stamm, Lingling Han, Diana M. Brainard, Norbert Bräu, Tarik Asselah, Bernard E. Willems, Steven Flamm, Marc Bourlière, Graham R. Foster, Edward J. Gane, Michael Manns, Stuart C. Gordon, Kris Kowdley
Published 2017-08-01